NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares, rose in value on Wednesday, June 18, with the stock price up by 2.08% to the previous day’s close as strong demand from buyers drove the stock to $2.45.
Actively observing the price movement in the last trading, the stock closed the session at $2.40, falling within a range of $2.3772 and $2.48. The value of beta (5-year monthly) was 1.599. Referring to stock’s 52-week performance, its high was $2.60, and the low was $0.51. On the whole, NRSN has fluctuated by 78.83% over the past month.
With the market capitalization of NeuroSense Therapeutics Ltd currently standing at about $58.77 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-07.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NRSN’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of NRSN currently trading nearly 29.49% and 74.12% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 78.60, while the 7-day volatility ratio is showing 2.22% which for the 30-day chart, stands at 5.73%. Furthermore, NeuroSense Therapeutics Ltd (NRSN)’s beta value is 1.63, and its average true range (ATR) is 0.20.
A comparison of NeuroSense Therapeutics Ltd (NRSN) with its peers suggests the former has fared considerably weaker in the market. NRSN showed an intraday change of 2.08% in last session, and over the past year, it grew by 152.58%%.
Data on historical trading for NeuroSense Therapeutics Ltd (NASDAQ:NRSN) indicates that the trading volumes over the past 10 days have averaged 0.57 and over the past 3 months, they’ve averaged 247.20K. According to company’s latest data on outstanding shares, there are 23.23 million shares outstanding.
Nearly 27.54% of NeuroSense Therapeutics Ltd’s shares belong to company insiders and institutional investors own 0.81% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.31 million shares as on 2025-05-30, resulting in a short ratio of 1.17. According to the data, the short interest in NeuroSense Therapeutics Ltd (NRSN) stood at 155.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 0.16 million. The stock has risen by 104.17% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NRSN stock heading into the next quarter.
